Home / Drugs (page 3)

Drugs

Information on pharmaceutical drugs, side effects and labelling

Elevations Health Center Treats Men and Women

Elevations Health Center Treats Men and Women Addiction is quite a challenge: Yet, if you have drug or alcohol issues, you shouldn’t feel ashamed. You didn’t take your first drink with the idea of becoming an alcoholic. Many addicts feel too ashamed or embarrassed to seek help for their disease. If …

Read More »

Effient (prasugrel)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 USE IN SPECIFIC POPULATIONS PLLR Conversion: Pregnancy Risk Summary There are no data with Effient use…

Read More »

Dulera (formoterol fumarate, mometasone furoate)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 USE IN SPECIFIC POPULATIONS PLLR Conversion: Pregnancy Risk Summary There are no randomized clinical studies… Powered by WPeMatico

Read More »

Dexilant (dexlansoprazole delayed-release capsules)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 ADVERSE REACTIONS Clinical Trials Experience Pediatrics (additional section added) The safety of DEXILANT…

Read More »

Clinolipid (lipid injectable emulsion)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 ADVERSE REACTIONS Post-marketing Experience Immune System Disorders: Hypersensitivity with the manifestations of rash..

Read More »

Asmanex HFA (mometasone furoate)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 USE IN SPECIFIC POPULATIONS PLLR Conversion: Pregnancy Risk Summary There are no randomized clinical studies…

Read More »

Alinia (nitazoxanide)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 PLR Conversion; please refer to label. ADVERSE REACTIONS (updated) Clinical Trials Experience Because clinical…

Read More »

Yondelis (trabectedin)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 WARNINGS AND PRECAUTIONS Hepatotoxicity Assess LFTs prior to each administration of YONDELIS and as clinically…

Read More »

Thallous Chloride T1201 Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 WARNINGS AND PRECAUTIONS Risk of Extravasation and Tissue Damage (and Tissue Damage added) Addition of:  Confirm…

Read More »